160 related articles for article (PubMed ID: 38313265)
1. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with
Kumar P; Koach J; Nekritz E; Mukherjee S; Braun BS; DuBois SG; Nasholm N; Haas-Kogan D; Matthay KK; Weiss WA; Gustafson C; Seo Y
Res Sq; 2024 Jan; ():. PubMed ID: 38313265
[TBL] [Abstract][Full Text] [Related]
2. Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
Wang SS; Hsiao R; Limpar MM; Lomahan S; Tran TA; Maloney NJ; Ikegaki N; Tang XX
Int J Mol Med; 2014 Jan; 33(1):35-42. PubMed ID: 24190252
[TBL] [Abstract][Full Text] [Related]
3. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
4. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
5. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
6. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
Défachelles AS; Cougnenc O; Carpentier P
Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
DuBois SG; Matthay KK
Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
[TBL] [Abstract][Full Text] [Related]
8. Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.
Rishfi M; Krols S; Martens F; Bekaert SL; Sanders E; Eggermont A; De Vloed F; Goulding JR; Risseeuw M; Molenaar J; De Wilde B; Van Calenbergh S; Durinck K
Eur J Med Chem; 2023 Feb; 247():115033. PubMed ID: 36549117
[TBL] [Abstract][Full Text] [Related]
9. Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells.
Yang Y; Ding L; Zhou Q; Fen L; Cao Y; Sun J; Zhou X; Liu A
Cancer Cell Int; 2020; 20():9. PubMed ID: 31920463
[TBL] [Abstract][Full Text] [Related]
10. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma.
Bogen D; Wei JS; Azorsa DO; Ormanoglu P; Buehler E; Guha R; Keller JM; Mathews Griner LA; Ferrer M; Song YK; Liao H; Mendoza A; Gryder BE; Sindri S; He J; Wen X; Zhang S; Shern JF; Yohe ME; Taschner-Mandl S; Shohet JM; Thomas CJ; Martin SE; Ambros PF; Khan J
Oncotarget; 2015 Nov; 6(34):35247-62. PubMed ID: 26497213
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
12. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
13. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
[TBL] [Abstract][Full Text] [Related]
14. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
Accorsi R; Morowitz MJ; Charron M; Maris JM
Pediatr Radiol; 2003 Oct; 33(10):688-92. PubMed ID: 12908090
[TBL] [Abstract][Full Text] [Related]
15. The Plasma Membrane Monoamine Transporter is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter.
Vieira LS; Zhang Y; López Quiñones AJ; Hu T; Singh DK; Stevens J; Prasad B; Park JR; Wang J
J Pharmacol Exp Ther; 2023 Dec; 387(3):239-248. PubMed ID: 37541765
[TBL] [Abstract][Full Text] [Related]
16. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
17. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
[TBL] [Abstract][Full Text] [Related]
18. Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma.
Ramani P; Nash R; Rogers CA
Histopathology; 2015 Feb; 66(3):370-9. PubMed ID: 25297850
[TBL] [Abstract][Full Text] [Related]
19. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
DuBois SG; Matthay KK
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):53-65. PubMed ID: 23474635
[TBL] [Abstract][Full Text] [Related]
20. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
